A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients
Latest Information Update: 08 Mar 2022
Price :
$35 *
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Mylan
- 01 Mar 2022 Status changed from active, no longer recruiting to completed.
- 09 Aug 2021 New trial record
- 29 Jun 2021 Primary endpoint has been met (Change in HbA1c), according Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association